
Single vaccine could protect against all coughs, colds and flus, researchers say
A Stanford University team have tested their nasal spray vaccine in animals but still need to do human clinical trials.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"This vaccine, what we term a universal vaccine, elicits a far broader response that is protective against not just the flu virus, not just the Covid virus, not just the common cold virus, but against virtually all viruses, and as many different bacteria as we've tested, and even allergens."
— Prof Bali Pulendran , Academic
"This is a really exciting piece of research."
— Prof Daniela Ferreira , Academic
"we have to ensure that keeping the body on 'high alert' doesn't lead to friendly fire, where a hyper-ready immune system accidentally triggers unwelcome side effects."
— Jonathan Ball , Academic
"I think what we have is a universal vaccine against diverse respiratory threats."
— Dr Bali Pulendran , Academic
"Traditional vaccines follow a model first introduced by Edward Jenner in the 18th century."
— Edward Jenner , Academic
"I think what we have is a universal vaccine against diverse respiratory threats."
— Bali Pulendran , Academic
Key People
He is the director of the Institute for Immunity, Transplantation and Infection at Stanford Medicine.
Lead author from Stanford Medicine who is researching a universal vaccine.
Edward Jenner was an English physician and scientist who pioneered the smallpox vaccine.
A professor of molecular virology at the Liverpool School of Tropical Medicine.
A professor of microbiology and immunology at Stanford University.
A professor of vaccinology at the University of Oxford.
Tags
All Coverage
A Stanford University team have tested their nasal spray vaccine in animals but still need to do human clinical trials.
Stanford University researchers are developing a single nasal spray that could protect against a vast array of respiratory illnesses, including common colds and flu, with early animal studies showing promising results.
Scientists at Stanford Medicine have developed a universal vaccine formula, tested on mice, that offers broad protection against various respiratory threats and could replace multiple annual jabs.
Researchers at Stanford University have developed a nasal spray vaccine that has shown promise in animal trials for protecting against various respiratory illnesses, including coughs, colds, and flus. Human clinical trials are forthcoming.
Experts at Stanford Medicine in the US have developed a universal vaccine that could be given as a nasal spray and could protect against a wide range of respiratory viruses, bacteria, and allergy triggers. Although the study, published in the journal Science, was in mice, they said the vaccine offered broad protection in the lungs for several months.
Stanford Medicine researchers have developed an intranasal vaccine that protects mice against respiratory viruses, bacteria, and allergens, potentially replacing multiple annual jabs.
A Stanford University team has tested a nasal spray vaccine in animals that could protect against various respiratory illnesses, but human clinical trials are still needed.
Scientists at Stanford Medicine have developed a universal vaccine formula, tested on mice, that offers broad protection against various respiratory threats. The vaccine, delivered as a nasal spray, could protect against cold, flu, Covid, allergies, respiratory viruses, sepsis-causing bacteria, and even house dust mites.
Similar Stories
Related coverage based on topic and tags
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMMorning Bid: Our products could end all human life, buy our shares - Reuters
Morning Bid: Our products could end all human life, buy our shares Reuters
September 29, 2026 at 04:33 AMChinese AI tool told researchers how to make bioweapons
Mindgard said it discovered in July that Kimi models K2.6 and K3 Swarm could evade developer's safety limits.
September 29, 2026 at 11:15 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMViruses run rampant across Havana as water, power fails - Reuters
Viruses run rampant across Havana as water, power fails Reuters
September 30, 2026 at 11:55 AM